Search
Multiple Sclerosis Paid Clinical Trials in Connecticut
A listing of 9 Multiple Sclerosis clinical trials in Connecticut actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 9 of 9
The state of Connecticut currently has 9 active clinical trials seeking participants for Multiple Sclerosis research studies. These trials are conducted in various cities, including New Haven, Hartford, Farmington and Stamford.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
High blood pressure (Hypertension) Trials
Recruiting
High blood pressure (Hypertension) trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
High blood pressure (Hypertension)
Featured Trial
Cardiovascular Disease Trials
Recruiting
Cardiovascular Disease trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Cardiovascular Disease
Featured Trial
Migraine Trials
Recruiting
Migraine trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Migraine
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Recruiting
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion crite... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
06/21/2024
Locations: New England Institute for Clinical Research Site Number : 8400114, Stamford, Connecticut
Conditions: Multiple Sclerosis
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Recruiting
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria.
Study details include:
This event... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
06/20/2024
Locations: New England Institute for Clinical Research Site Number : 8400114, Stamford, Connecticut
Conditions: Multiple Sclerosis
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis or Progressive Forms of Multiple Sclerosis
Recruiting
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS) or Progressive Forms of Multiple Sclerosis (PMS).
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
06/14/2024
Locations: Local Institution - 0032, New Haven, Connecticut
Conditions: Multiple Sclerosis
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Recruiting
This Phase 2 trial will assess the safety, tolerability, efficacy, imaging pharmacodynamics, and pharmacokinetics of RVP-001, a novel manganese-based MRI contrast agent, at three escalating dose levels. RVP-001 will be administered as a single IV bolus to subjects with known gadolinium-enhancing central nervous system (CNS) lesions (for example stable brain tumor or multiple sclerosis) who have recently had a gadolinium-based contrast agent (GBCA)-enhanced MRI of the brain.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/12/2024
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign, Brain Tumor, Primary, Brain Tumor, Recurrent, Brain Tumors, Brain Cancer, Brain Tumor, Brain Neoplasm, Primary, Multiple Sclerosis, Multiple Sclerosis Brain Lesion, Neurofibroma, Acoustic Neuroma, CNS Tumor, CNS Lesion, CNS Metastases, CNS Cancer, CNS Lymphoma
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut +1 locations
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 in Participants With Multiple Sclerosis.
Recruiting
The primary purpose of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) (Part 1) and subcutaneous (SC) (Part 2) doses of RO7121932 and multiple ascending SC (Part 3) doses of RO7121932 in participants with multiple sclerosis (MS).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/07/2024
Locations: Yale University Multiple Sclerosis Center, New Haven, Connecticut
Conditions: Multiple Sclerosis
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
Recruiting
This study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS. All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6 and Month 12. At Month 12, participants will be randomized (1:1:1) to one of three Arms with randomized treatm... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
05/13/2024
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Multiple Sclerosis
Intestinal Immunity in Neurologic Disease
Recruiting
The purpose of this study is to ascertain the functional profiles of the immune cells within the gastrointestinal tract and to determine how these cells contribute to autoimmune and neurologic diseases.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
03/22/2024
Locations: Yale MS Clinic, North Haven, Connecticut
Identifying and Characterizing Preclinical MS
Recruiting
The purpose of this research study is to try and identify risk factors and biologic changes that suggest that someone may go on to develop multiple sclerosis before a person has shown any symptoms of the disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/04/2024
Locations: Yale University, North Haven, Connecticut
Conditions: Multiple Sclerosis
1 - 9 of 9